STEP 1 Trial Explained: Semaglutide 2.4 mg for Obesity in 2 Minutes

Can once-weekly semaglutide produce meaningful weight loss in adults with obesity?In this 2-minute evidence brief, we break down the STEP 1 trial, a randomized double-blind clinical trial published in the New England Journal of Medicine in 2021. The study tested semaglutide 2.4 mg once weekly versus placebo, both with lifestyle intervention, in adults with overweight or obesity but without diabetes.Covered in this video:Why the STEP 1 trial was doneHow the trial was conductedMain weight loss resultsSafety and gastrointestinal side effectsKey clinical takeawayMain result: average body weight decreased by 14.9% with semaglutide versus 2.4% with placebo over 68 weeks.Citation:Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.PMID: 33567185DOI: 10.1056/NEJMoa2032183This video is for medical education only and does not replace clinical judgment or individual medical advice.#Semaglutide #STEP1Trial #ObesityMedicine #GLP1 #MedicalEducationsemaglutide, STEP 1 trial, semaglutide obesity, semaglutide weight loss, Wegovy, GLP-1 receptor agonist, obesity treatment, obesity medicine, clinical trial explained, randomized controlled trial, RCT, NEJM, weight loss medication, semaglutide 2.4 mg, evidence based medicine, medical education, endocrinology, hormone insight, GLP-1 weight loss, obesity pharmacotherapy